赖诺普利治疗系统性红斑狼疮患者尿蛋白的临床研究

Clinical research of lisinopril in treating proteinuria in patients with systemic lupus erythematosus

目的探讨赖诺普利对系统性红斑狼疮(SLE)患者尿蛋白的作用。方法将72例SLE患者随机分为两组,赖诺普利治疗组(治疗组)39例及非赖诺普利治疗组(对照组)33例。治疗组给予赖诺普利10 mg/d,总疗程为8周。治疗8周后,与治疗前及对照组比较,观察24 h尿蛋白定量等指标的变化。结果在降尿蛋白的疗效比较中,治疗组显著优于对照组(P<0.01)。治疗组在治疗后24 h尿蛋白明显下降(P<0.01)。对照组下降不明显(P>0.05)。两组血压均有下降,但差异无统计学意义(P>0.05)。主要不良反应是咳嗽、血钾轻度升高,但不影响治疗。结论赖诺普利可有效地降低SLE患者的尿蛋白,对SLE患者的肾脏有较好的保护作用。

Objective To evaluate the efficacy of Lisinopril in treating proteinuria in patients with Systemic Lupus Erythematosus（SLE）.Methods 72 cases of SLE with urine protein were randomized into two groups,39 cases in the Lisinopril-treated group,the other 33 cases in the control group.The Lisinopril-treated group was orally given Lisinopril（10 mg,Qd） for 8 weeks.Before and after the study,Such as twenty-four hours urinary protein content indexs were investigated.Results The efficacy of decreasing urine protein,the treating group had statistical significance higher than the control group（P0.01）.In the treating group,twenty-four hours urinary protein content was markedly decreased（P0.01）.By contrast,twenty-four hours urinary protein content did not show any significant change in control group（P0.05）,the blood pressure decreased in the control,but had no statistical significance（P0.05）.The most common adverse events were cough and blood potassium mild increased during Lisinopril treatment,but those did not affect treatment.Conclusion Lisinopril decreases proteinuria efficiently in the Systemic Lupus Erythematosus patients,Lisinopril may safeguard the kidney in SLE patients.